Design and baseline characteristics of the LANDMARK study

about

A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?

P2860

Q38741675-B9AF27AB-7925-4A1B-9DAE-EEDBC8F01847

P2860

Design and baseline characteristics of the LANDMARK study

Item

http://www.wikidata.org/entity/Q41389097

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Design and baseline characteristics of the LANDMARK study

@en

type

Item

label

Design and baseline characteristics of the LANDMARK study

@en

prefLabel

Design and baseline characteristics of the LANDMARK study

@en

P1476

Design and baseline characteristics of the LANDMARK study

@en

P2093

Hideaki Kaneda

http://www.w3.org/2001/XMLSchema#string

Hideki Hirakata

http://www.w3.org/2001/XMLSchema#string

LANDMARK Study Group

http://www.w3.org/2001/XMLSchema#string

Tadao Akizawa

http://www.w3.org/2001/XMLSchema#string

Tatsuo Kagimura

http://www.w3.org/2001/XMLSchema#string

P2860

Definition and Evaluation of Transient Ischemic Attack

Phosphate regulation of vascular smooth muscle cell calcification

Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data.

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.

Novel cardiovascular risk factors in end-stage renal disease.

Hyperphosphatemia in renal failure.

CKD-MBD: impact on management of kidney disease.

Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.

Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients.

Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy.

P2888

s10157-016-1310-8

P304

531-537

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10157-016-1310-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hiroaki Ogata

Masafumi Fukagawa

P577

2016-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27405619

http://www.w3.org/2001/XMLSchema#string

P932

5556131

http://www.w3.org/2001/XMLSchema#string

Design and baseline characteristics of the LANDMARK study

about

P2860

P2860

Design and baseline characteristics of the LANDMARK study

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P932